About Traumen Life Sciences
Traumen Life Sciences offers products and services including Allopathic Medicines and Customized Packaging.
- SectorsHealthcareConsumer
- Email••••••••
- Legal Name Traumen Life Sciences Pvt Ltd
- Date of Incorporation 15 May, 2015
- Jurisdiction Virar West, Maharashtra, India
- Annual Revenue₹0.68 Cr
FY 2022 · +43% YoY
- Net Profit₹0.01 Cr
FY 2022 · 2% margin
- EBITDA₹0.02 Cr
FY 2022 · 2% margin
Associated legal entities of Traumen Life Sciences
Traumen Life Sciences operates through Traumen Life Sciences Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2022) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Traumen Life Sciences Private Limited CIN U24233MH2015PTC264497 | Active | 15 May 2015 | Virar West, Maharashtra | ₹0.7 Cr | – | 3 | View details |
Products & Services of Traumen Life Sciences
Traumen Life Sciences offers a comprehensive portfolio of products and services, including Allopathic Medicines and Customized Packaging.
Manufacturing and marketing of Allopathic medicines are conducted to address various physical ailments.
Customized packaging solutions are provided to fulfill customer and market requirements.
Board of directors of Traumen Life Sciences Private Limited (Traumen Life Sciences)
Traumen Life Sciences Private Limited is the primary company behind Traumen Life Sciences. The board of Traumen Life Sciences Private Limited currently have 3 directors; the longest-serving is Saurabh Kumar Srivastava, appointed in 2015.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Saurabh Kumar Srivastava DIN 07153059 | Director | 15 May 2015 | 11 yrs 4 mo | Traumen Life Sciences Private Limited |
| Narendra Bhojesing Jamadar DIN 07153104 | Director | 15 May 2015 | 11 yrs 4 mo | Traumen Life Sciences Private Limited |
| Chetan Kumar Verma DIN 07153048 | Director | 15 May 2015 | 11 yrs 4 mo | Traumen Life Sciences Private Limited |
Financials of Traumen Life Sciences
Figures of Traumen Life Sciences Private Limited, the primary company behind Traumen Life Sciences, for FY 2022. Revenue was ₹0.68 Cr (+43% year on year). Net profit was ₹0.01 Cr (2% margin). EBITDA was ₹0.02 Cr (2% margin). Revenue has grown at a compounded annual rate of +16% over three years.
- ₹0.68 CrRevenue · FY 2022 · +43% YoY
- ₹0.01 CrNet profit · 2% margin
- ₹0.02 CrEBITDA · 2% margin
- ₹0.01 CrPaid-up capital
- +16%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Traumen Life Sciences Private Limited are on its company page.
Detailed financial statements for Traumen Life Sciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Similar companies to Traumen Life Sciences
10 companies that operate in the same segment as Traumen Life Sciences (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Traumen Life Sciences
The primary company behind Traumen Life Sciences, Traumen Life Sciences Private Limited, reported revenue of ₹0.68 Cr for FY 2022, up 43% year on year.
Traumen Life Sciences is involved in the manufacturing and marketing of Allopathic medicines as part of the pharmaceutical ecosystem. A deep sense of responsibility is demonstrated to cure diseases and alleviate human suffering caused by physical ailments. High-quality pharmaceutical products are assured, accompanied by timely delivery services. Customized packaging solutions are also provided to align with customer and market needs, ensuring effective distribution and accessibility.
Traumen Life Sciences offers Allopathic Medicines and Customized Packaging.
Traumen Life Sciences operates through Traumen Life Sciences Private Limited.
The legal entities of Traumen Life Sciences currently have 3 directors, including Saurabh Kumar Srivastava, Narendra Bhojesing Jamadar, Chetan Kumar Verma.